MEDTIDE(03880),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

03880 MEDTIDE

Trading 06-18 10:40:29

22.400

+0.000

0.00%

High22.700	Low22.160	Vol32.20K
Open22.500	D1 Closing22.400	Amplitude2.41%
Mkt Cap3.18B	Tradable Cap3.18B	Total Shares141.80M
T/O723.94K	T/O Rate0.02%	Tradable Shares141.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"03880","market":"HK","secType":"STK","nameCN":"MEDTIDE","latestPrice":22.4,"timestamp":1781750240318,"preClose":22.4,"halted":0,"volume":32200,"delay":0,"changeRate":0,"floatShares":141800000,"shares":141800000,"eps":1.8882646176030344,"marketStatus":"Trading","change":0,"latestTime":"06-18 10:40:29","open":22.5,"high":22.7,"low":22.16,"amount":723942,"amplitude":0.024107,"askPrice":22.44,"askSize":1200,"bidPrice":22.1,"bidSize":400,"shortable":0,"etf":0,"ttmEps":1.965880402498374,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1781755200000},"marketStatusCode":2,"adr":0,"listingDate":1751212800000,"exchange":"SEHK","adjPreClose":22.4,"openAndCloseTimeList":[[1781746200000,1781755200000],[1781758800000,1781769600000]],"volumeRatio":1.440165,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03880/wiki","defaultTab":"wiki","newsList":[{"id":"2642826232","title":"Precision Peptide plans non-brokered private placement of up to 4,000,000 shares at $0.5 each, targeting up to $2 million gross proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2642826232","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642826232?lang=en_us&edition=fundamental","pubTime":"2026-06-12 05:01","pubTimestamp":1781211680,"startTime":"0","endTime":"0","summary":"Precision Peptide plans non-brokered private placement of up to 4,000,000 shares at $0.5 each, targeting up to $2 million gross proceeds. The Precision Peptide Company launched a non-brokered private placement of 3,000,000 to 4,000,000 common shares at $0.5 each.Gross proceeds targeted at $1.5 million to $2 million.Net proceeds earmarked for working capital, marketing, inventory, and products.Closing expected on or about June 25, 2026, with the financing potentially completed in tranches.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL12Pxwn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642491185","title":"Medtide Says CPC Scientific Enters Construction Contracts For Rocklin Site On Aug 7, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2642491185","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642491185?lang=en_us&edition=fundamental","pubTime":"2026-06-10 01:11","pubTimestamp":1781025066,"startTime":"0","endTime":"0","summary":"June 9 (Reuters) - Medtide <3880.HK>::*CPC SCIENTIFIC ENTERS CONSTRUCTION CONTRACTS FOR ROCKLIN SITE AT MAX PRICE OF $22.7 MILLION ON AUG 7, 2025*Further company coverage: 3880.HK* ((Reuters.Briefs@th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nRSD62NMhC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149779263","title":"MEDTIDE's Subsidiary Signs Construction Contract with Market One Builders for Rocklin Campus","url":"https://stock-news.laohu8.com/highlight/detail?id=1149779263","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149779263?lang=en_us&edition=fundamental","pubTime":"2026-06-09 20:54","pubTimestamp":1781009664,"startTime":"0","endTime":"0","summary":"The company's wholly-owned subsidiary, CPC Scientific Inc., has entered into a construction contract with Market One Builders for the development of the Rocklin campus, with a guaranteed maximum...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642146037","title":"Medtide - Cpc Scientific Enters Construction Contracts for Rocklin Site at Max Price of $22.7 Mln on Aug 7, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2642146037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642146037?lang=en_us&edition=fundamental","pubTime":"2026-06-09 20:39","pubTimestamp":1781008773,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nFWN42H0K1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["03880","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642313460","title":"Medtide unit CPC Scientific signs USD 22.72 million Rocklin construction contract with Market One Builders","url":"https://stock-news.laohu8.com/highlight/detail?id=2642313460","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642313460?lang=en_us&edition=fundamental","pubTime":"2026-06-09 20:39","pubTimestamp":1781008745,"startTime":"0","endTime":"0","summary":"Medtide’s CPC Scientific unit signed construction contracts with Market One Builders for its Rocklin, California manufacturing site.Guaranteed maximum price set at USD 22.72 million under a cost-plus structure with a 3.5% contractor fee.Work starts within seven days of a notice to proceed; substantial completion targeted within 396 calendar days from start.Facility is expected to add up to 300 kg of annual peptide API capacity once completed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtide Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL9v6Wt9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122293097","title":"Medtide: No Share Capital Movements in May 2026, Public Float Meets 25% Threshold","url":"https://stock-news.laohu8.com/highlight/detail?id=1122293097","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122293097?lang=en_us&edition=fundamental","pubTime":"2026-06-03 17:05","pubTimestamp":1780477517,"startTime":"0","endTime":"0","summary":"Medtide Inc. (H-share, HKEX: 03880) reported no changes to its share capital structure for the month ended 31 May 2026, according to the company’s monthly return filed on 3 June 2026. • Issued Share...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640171429","title":"Precision Peptide issues 300,000 shares at $0.42 to settle $125,000 CEO debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2640171429","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640171429?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:22","pubTimestamp":1780399330,"startTime":"0","endTime":"0","summary":"The Precision Peptide Company settled USD 125,000 of debt by issuing 300,000 common shares at a deemed price of USD 0.42 each.The debt represented an unpaid cash bonus owed to CEO Pratap Sandhu.The shares carry a statutory hold period of four months plus one day.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Precision Peptide Company Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDLb9933:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640917815","title":"Precision Peptide signs compounding deal with US 503A sterile pharmacy partner","url":"https://stock-news.laohu8.com/highlight/detail?id=2640917815","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640917815?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:04","pubTimestamp":1780398295,"startTime":"0","endTime":"0","summary":"The Precision Peptide Company signed a compounding agreement with a U.S.-based 503A sterile compounding pharmacy for prescription peptide fulfillment.Work is expected to start June 1, 2026, with capacity of up to 25,000 prescriptions per day across all U.S. states.Products under the deal will be 100% compounded in the United States, including BPC-157.The partner’s identity was not disclosed.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL5z4dz8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637339033","title":"Precision Peptide expands exclusive revenue-share marketing partnership with MMA.INC","url":"https://stock-news.laohu8.com/highlight/detail?id=2637339033","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637339033?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:55","pubTimestamp":1779364508,"startTime":"0","endTime":"0","summary":"The Precision Peptide Company expanded details on an exclusive strategic marketing agreement with MMA.INC that gives it exclusive marketing rights across MMA.INC’s global combat sports platform.Net revenue from MMA-sourced customer sales will be split 50/50 for the first 12 months, shifting to a 75/25 split in Precision’s favor for the rest of the term.The agreement includes a 12-month post-termination revenue-sharing tail on sales to MMA-referred customers.Precision will sell U.S.-manufactured, third-party-tested peptide products into MMA.INC’s ecosystem of more than 5 million social followers, about 530,000 user profiles, 75,000 active students, and more than 800 verified gyms.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Preci","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL7lsptf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216594","title":"Precision Peptide signs exclusive marketing partnership with Mixed Martial Arts Group Limited","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216594","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216594?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:50","pubTimestamp":1778586616,"startTime":"0","endTime":"0","summary":"Precision Peptide Company entered exclusive strategic marketing agreement with Mixed Martial Arts Group dated May 8, 2026 to market peptide products to MMA subscriber base.Partnership targets MMA digital ecosystem of more than 5 million social media followers, about 530,000 user profiles, over 75,000 active students, more than 800 verified gyms globally.Net revenue from MMA-sourced sales to be split 50%/50% for first 12 months, shifting to 75% for Precision Peptide Company, 25% for MMA from month 13.Either party can terminate with 30 days’ written notice; MMA profit share continues for 12 months on customers referred during term.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Precision Peptide Company Inc. published the original co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL360Km5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160432466","title":"Medtide: April 2026 Monthly Return Confirms Unchanged 141.80 Million H-Share Capital and Adequate Public Float","url":"https://stock-news.laohu8.com/highlight/detail?id=1160432466","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160432466?lang=en_us&edition=fundamental","pubTime":"2026-05-06 17:05","pubTimestamp":1778058300,"startTime":"0","endTime":"0","summary":"Medtide Inc. filed its Monthly Return for the period ended 30 April 2026 with Hong Kong Exchanges and Clearing on 6 May 2026, reporting no movements in either authorised or issued share capital. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168795308","title":"MEDTIDE 2025年营收同比增长28.9%，净利大幅提升并完成上市后资本结构优化","url":"https://stock-news.laohu8.com/highlight/detail?id=1168795308","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168795308?lang=en_us&edition=fundamental","pubTime":"2026-04-23 22:47","pubTimestamp":1776955636,"startTime":"0","endTime":"0","summary":"根据MEDTIDE发布的2025年度香港上市公司年报摘要，报告期内公司整体经营表现显著提升，并顺利完成首次公开募股，推动资本结构与业务布局进一步优化。...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"MEDTIDE 2025年营收同比增长28.9%，净利大幅提升并完成上市后资本结构优化","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629853555","title":"Medtide publishes 2025 ESG report","url":"https://stock-news.laohu8.com/highlight/detail?id=2629853555","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629853555?lang=en_us&edition=fundamental","pubTime":"2026-04-23 22:42","pubTimestamp":1776955350,"startTime":"0","endTime":"0","summary":"Medtide released its first ESG report, outlining 2025 performance across governance, product responsibility, workforce, and environmental management.Scope 1 and Scope 2 greenhouse gas emissions totaled 9,518 tCO2e, with emissions intensity at 0.17 tCO2e per RMB 10,000 of revenue.Air emissions metrics showed particulate matter at 0.22 tonnes, with VOC emissions at 0.67 tonnes.Operational risk indicators included zero product recalls for safety or health reasons, with 0 confirmed corruption cases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtide Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 23, 2026, and is solely res","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL8nH79j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629719858","title":"Medtide publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2629719858","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629719858?lang=en_us&edition=fundamental","pubTime":"2026-04-23 22:32","pubTimestamp":1776954764,"startTime":"0","endTime":"0","summary":"Medtide released 2025 annual report, highlighting June 2025 Hong Kong listing as key milestone.Full-year performance set new records, supported by stronger demand across integrated peptide CRDMO services.Commercial-scale peptide API capacity expanded in second half, lifting annual output capability to over 1 metric ton with single-batch runs above 50 kg.Project pipeline ended year with 1,614 ongoing programs, including 9 NCE GLP-1 development projects across 7 customers.US Rocklin site buildout advanced, targeting 300 kg annual capacity to support localized GMP peptide API supply.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtide Inc. published the original content used to generate this news brief via IIS, the Issuer Information S","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL7zvsJg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627297342","title":"Precision Peptide grants 800,000 stock options to consultants at $0.5 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2627297342","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627297342?lang=en_us&edition=fundamental","pubTime":"2026-04-16 19:31","pubTimestamp":1776339109,"startTime":"0","endTime":"0","summary":"Precision Peptide Company granted 800,000 stock options to certain consultants under its omnibus long-term incentive plan.Options carry an exercise price of $0.5 per common share.Terms run from one year to three years from grant date.Shares issued on option exercise will be subject to a four-month hold period from grant date.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL5l8fng:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117575956","title":"Medtide Doubles Issued Share Capital to 141.80 Million Shares through Conversion of 68.20 Million Unlisted Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1117575956","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117575956?lang=en_us&edition=fundamental","pubTime":"2026-04-08 18:00","pubTimestamp":1775642459,"startTime":"0","endTime":"0","summary":"Medtide Inc. filed its Monthly Return for Equity Issuer for March 2026, detailing a major capital restructuring that brings all outstanding shares onto The Stock Exchange of Hong Kong (HKEX). Key...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624080539","title":"Medtide (SEHK:3880) Net Margin Surge In 1H FY 2025 Tests Earnings Quality Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2624080539","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624080539?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:20","pubTimestamp":1774963251,"startTime":"0","endTime":"0","summary":"Medtide (SEHK:3880) has just posted its FY 2025 first half numbers, with revenue of ¥253.8 million and basic EPS of ¥0.82, set against trailing twelve month revenue of ¥570.1 million and EPS of ¥1.63 that sit alongside a reported year over year earnings growth figure of 267.3%. Over recent periods the company has seen revenue move from ¥197.5 million and EPS of ¥0.40 in the first half of FY 2024 to ¥244.8 million and EPS of ¥0.07 in the second half of FY 2024 and then to the latest ¥253.8...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3880/medtide-shares/news/medtide-sehk3880-net-margin-surge-in-1h-fy-2025-tests-earnin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3880/medtide-shares/news/medtide-sehk3880-net-margin-surge-in-1h-fy-2025-tests-earnin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1141","03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176842672","title":"Medtide 2025 Results: Revenue Reaches RMB570.09 Million, Net Profit Soars 267.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1176842672","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176842672?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:46","pubTimestamp":1774874819,"startTime":"0","endTime":"0","summary":"Medtide Inc. released its audited results for the year ended 31 December 2025. Revenue increased 28.9% year-on-year to RMB570.09 million, driven mainly by strong growth in CDMO services. Net profit...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176147559","title":"Medtide Proposes Articles Revision and Scraps Supervisory Committee in Line with New PRC Company Law","url":"https://stock-news.laohu8.com/highlight/detail?id=1176147559","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176147559?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:46","pubTimestamp":1774874818,"startTime":"0","endTime":"0","summary":"Medtide Inc. (stock short name: MEDTIDE) announced that its Board of Directors resolved on 30 March 2026 to overhaul the company’s governance framework by amending its Articles of Association and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623131044","title":"Medtide proposes bylaw amendments to replace supervisory committee with board audit committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2623131044","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623131044?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:42","pubTimestamp":1774874555,"startTime":"0","endTime":"0","summary":"Medtide set proposed amendments to articles of association for shareholder vote at a forthcoming annual general meeting.Changes would abolish supervisory committee, shifting its functions to board audit committee under revised PRC Company Law effective July 1, 2024.Package also targets stronger shareholder protections, aligning governance rules with updated PRC regulations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtide Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 30, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL9HRwvH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880","BK1141"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.medtideinc.com","stockEarnings":[{"period":"1week","weight":0.0853},{"period":"1month","weight":0.0081},{"period":"3month","weight":0.0009},{"period":"6month","weight":-0.2453},{"period":"1year","weight":-0.268},{"period":"ytd","weight":-0.2651}],"compareEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":-0.0531},{"period":"3month","weight":-0.0466},{"period":"6month","weight":-0.0537},{"period":"1year","weight":0.0138},{"period":"ytd","weight":-0.0514}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Medtide Inc is a China-based company mainly engaged in the contract research, development and manufacturing of peptide. The Company mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The Company's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The Company also provides customers with peptide drug development, production, and CMC filing support services. The Company mainly operates its business in the domestic market and overseas markets.","exchange":"SEHK","name":"MEDTIDE","nameEN":"MEDTIDE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MEDTIDE(03880),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MEDTIDE(03880) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MEDTIDE,03880,MEDTIDE股票,MEDTIDE股票老虎,MEDTIDE股票老虎国际,MEDTIDE行情,MEDTIDE股票行情,MEDTIDE股价,MEDTIDE股市,MEDTIDE股票价格,MEDTIDE股票交易,MEDTIDE股票购买,MEDTIDE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MEDTIDE(03880),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MEDTIDE(03880) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}